Does Orforglipron Increase Heart Rate? What the Label Says

Yes — orforglipron (Foundayo) is associated with a measurable increase in heart rate in clinical trials, and it’s listed as an identified side effect on the FDA-approved label. For most people the increase is small and not something they notice day to day, but it’s worth understanding the actual numbers, how it compares to other GLP-1 medications, and what would be worth a call to your prescriber.

What the FOUNDAYO label actually reports

Per the FDA-approved FOUNDAYO (orforglipron) label on DailyMed, treatment was associated with:

• A mean increase in heart rate of about 4 to 5 beats per minute from baseline across trials, compared with about 0.5 beats per minute on placebo.
• Tachycardia (captured in the label as tachycardia, heart rate increased, or sinus tachycardia) reported in about 3% of people treated with orforglipron, versus about 0.9% on placebo.

That’s the specific, sourced number — not a guess. A few beats per minute on average is a modest shift for most people, but it’s real enough that it’s part of the label’s documented side-effect profile, not an internet rumor.

Is this specific to orforglipron, or a GLP-1 class effect?

It’s a class effect, not something unique to orforglipron. Both MedlinePlus drug information pages for other GLP-1 medications list a fast, pounding, or irregular heartbeat among the effects to be aware of:

GLP-1 medicine	What the source says about heart rate
Orforglipron (Foundayo)	Mean increase of ~4–5 bpm vs. ~0.5 bpm on placebo; tachycardia in ~3% vs. ~0.9% on placebo (FOUNDAYO label, DailyMed)
Semaglutide — injection (Ozempic, Wegovy)	Fast, pounding, or irregular heartbeat listed among side effects to report to your doctor (MedlinePlus)
Semaglutide — oral (Rybelsus)	Same active ingredient as injectable semaglutide; fast or irregular heartbeat listed among effects to report (MedlinePlus)
Tirzepatide (Mounjaro, Zepbound)	Fast, pounding, or irregular heartbeat listed among side effects to report to your doctor (MedlinePlus)

None of these sources publish a head-to-head comparison of exactly how much each drug raises heart rate relative to the others, so this article won’t manufacture one. What’s consistent across them is the same underlying message: a heart rate change is a recognized possibility with GLP-1 receptor agonists as a class, and it’s something your prescriber wants to know about, whichever one you’re on.

If you’re weighing orforglipron against a specific alternative more broadly — not just this one side effect — Orforglipron vs Ozempic and Orforglipron vs Tirzepatide cover the fuller comparison.

Why would a GLP-1 medication affect heart rate at all?

This article isn’t the place to explain the underlying physiology in clinical depth, and doing so isn’t necessary to answer the practical question. What matters for you as a patient is simpler: the FDA-approved label documents the effect, gives you real numbers to calibrate against, and the same pattern shows up in drug information for other medications in the same class. That’s enough to know it’s a genuine, monitored side effect — not enough, on its own, to tell you what it means for your specific health situation. That’s a question for your prescriber.

What this looks like day to day

For most people, a 4–5 beats-per-minute average increase isn’t something you’d notice without checking a pulse or wearable device. It’s also an average — some people see more of a change, some see less or none. A smartwatch or fitness tracker that logs resting heart rate can be a useful, low-effort way to notice a trend over your first few weeks or during a dose increase, without needing to interpret it yourself. If you’re just starting out, First Week on Orforglipron covers what else tends to show up early.

When to contact your prescriber

This is educational information, not a personal risk assessment — only your prescriber can tell you what’s expected for you. That said, general guidance reflected in GLP-1 drug labeling points toward reasons to reach out rather than wait it out:

• A resting heart rate that stays elevated rather than settling over time.
• A noticeably pounding, racing, or fluttering heartbeat (palpitations), especially alongside chest discomfort, shortness of breath, dizziness, or fainting.
• Any new heart symptom if you already have a heart condition, since your baseline risk is different from someone without one.

Should you stop orforglipron over a heart rate change?

Don’t decide that on your own. Whether a heart rate increase on orforglipron is expected for you, needs monitoring, or should change your treatment plan depends on your baseline heart rate, your medical history, and what your prescriber sees when they check you — not on a general article. If you notice a change, the right move is a conversation with them, not stopping or adjusting the medication yourself. For a fuller rundown of the other side effects orforglipron is associated with, see Orforglipron Side Effects: What to Expect and How to Manage Them, and if you’re on other medications, Orforglipron Drug Interactions is worth a read too.

Bottom line

Orforglipron (Foundayo) is associated with a small average increase in heart rate — about 4 to 5 beats per minute versus roughly 0.5 on placebo — and tachycardia was reported in about 3% of people on the drug versus 0.9% on placebo, per its FDA-approved label. It’s a documented, class-wide effect shared with other GLP-1 medications like semaglutide and tirzepatide, not something unique to orforglipron. For most people it’s a minor shift, but a persistently elevated heart rate or symptoms like palpitations, chest pain, or fainting are worth raising with your prescriber promptly. For the full dosing and administration picture, see Foundayo (Orforglipron): A Simple Guide.